Home Topics Cancer Two by 2025: MorphoSys Consolidates Research, Retains Commercialization Goal

sw7-mor_0263_0-600x341 — Two months after laying out plans for bringing a second drug to market by 2025 and building a pipeline of oncology and hematology therapies, MorphoSys says it remains committed to those goals while changing how it plans to accomplish them—by focusing on later-stage clinical programs and consolidating in Europe its research operations, which expanded Stateside last year when the company acquired Constellation Pharmaceuticals. [MorphoSys]

Two by 2025: MorphoSys Consolidates Research, Retains Commercialization Goal

Company eyes Pelabresib as second marketed drug, commits to advancing CPI-0209 and felzartamab, building pipeline in oncology and hematology

By Alex Philippidis

March 15, 2022

Two months after laying out plans for bringing a second drug to market by 2025 and building a pipeline of oncology and hematology therapies, MorphoSys says it remains committed to those goals while changing how it plans to accomplish them—by focusing on later-stage clinical programs and consolidating in Europe its research operations, which expanded Stateside last year when the company acquired Constellation Pharmaceuticals. [MorphoSys]

Morphosys said it would concentrate its research activities on its most advanced programs for its four top drugs. The four begin with Monjuvi® (tafasitamab-cxix), marketed as a therapy for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with lenalidomide; and Pelabresib (CPI-0610), being studied as a first-line treatment for myelofibrosis. MorphoSys has also committed to advancing CPI-0209, developed to treat advanced solid tumors and hematologic malignancies; and felzartamab, developed to treat Immunoglobulin A nephropathy and anti-PLA2R-positive membranous nephropathy . . .